RCS - Verici Dx PLC - New data to be presented at ATC

Verici DxAnnouncement

24/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240524:nRSX7206Pa&default-theme=true

RNS Number : 7206P  Verici Dx PLC  24 May 2024

Non-regulatory announcement

Verici Dx plc

("Verici Dx" or the "Company")

 

New data to be presented at American Transplant Conference

Important potential role of Tutivia(TM) as a novel risk assessment tool in the
context of delayed graft function ("DGF")

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces it will attend the American Transplant Congress
("ATC") in Philadelphia hosted by the American Society of Transplantation and
the American Society of Transplant Surgeons from 1-5 June 2024. We look
forward to sharing our work on "Performance of Next-Gen Sequencing Biomarker
Tutivia(TM) in the Setting of Kidney Delayed Graft Function" on Saturday 1
June 2024, as well as meeting with others to discuss ideas and opportunities
at ATC_Booth-215.

 

ATC provides a forum for the exchange of new scientific data and clinical
information relevant to solid organ and tissue transplantation. The event
brings together transplant physicians, scientists, nurses, organ procurement
personnel, pharmacists, allied health professionals and other transplant
professionals.

 

Commenting on the conference, Dr. Joshua Lee, VP Medical Affairs said:

 

"DGF is a condition that can lead to a higher risk of rejection. Identifying
which patients are likely to experience rejection in this population is an
unmet need in transplantation. Verici Dx is excited to present findings in
this population from our clinical trial at this prestigious conference.

 

ATC in Philadelphia is such a great venue to bring together the global
transplant community. We are looking forward to discussions in the halls and
seeing friends in the community, as well as learning about new developing
approaches to treatments and diagnostics that can make the lives of transplant
patients better."

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     investors@vericidx.com
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: +44 20 7496 3000
 Aubrey Powell / Sam Butcher

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes. The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage. The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology, including through collaboration with medical device,
biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFSSELIVFIS